Jaguar Health Stock Price - JAGX

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 0.60 ▲ 0.02 (3.36%)
Company Name Stock Ticker Symbol Market Type
Jaguar Health Inc JAGX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0266 -4.38% 0.5805 0.62 0.5712 0.60 0.6071 00:00:07
Bid Price Ask Price Spread Spread % News
0.58 0.64 0.06 9.38% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,267 332,805 $ 0.597612 $ 198,888 875,528 0.56 - 38.50
Last Trade Time Type Quantity Stock Price Currency
18:43:38 25 $ 0.5905 USD

Jaguar Health Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 7.88M 13.58M $ -32.15M -153.56 - 13.57M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 0.10%

more financials information »

Jaguar Health News

Loading Messages....

Latest JAGX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical JAGX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.610.700.570.6336377340,080-0.0295-4.84%
1 Month0.7461.220.560.86453781,170,918-0.1655-22.18%
3 Months1.341.690.561.00893,051-0.7595-56.68%
6 Months10.53516.980.562.851,042,816-9.95-94.49%
1 Year30.4538.500.5617.092,807,017-29.87-98.09%
3 Years47.60224.000.5623.172,580,841-47.02-98.78%
5 Years490.00494.200.5625.471,734,039-489.42-99.88%

Jaguar Health Description

Jaguar Health Inc is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products. The company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the marketplace from plants used traditionally in rainforest areas. It operates into two business segments namely Humal health and animal health. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Your Recent History
Jaguar Hea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.